课题基金 / 基金详情

HU23F2G IN ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS

HU23F2G IN ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS
多发性硬化症急性加重中的 HU23F2G
批准号：
6121136
负责人：
Jerry Saul Wolinsky
金额：
$1.51万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6121136
关键词：
clinical research drug screening /evaluation hormone therapy human subject human therapy evaluation immunotherapy methylprednisolone monoclonal antibody multiple sclerosis

项目摘要

项目成果

Jerry Saul Wolinsky的其他基金

相关文献

中文摘要
翻译
该研究被设计为评估与安慰剂和皮质类固醇治疗相比，静脉内给予患有多发性硬化症（MS）急性加重的患者的Hu 23 F2 G的功效和安全性。Hu 23 F2 G是一种人源化抗CD 18单克隆抗体，其在MS的非人灵长类动物实验模型中有效。这是一项2期研究，其中患者将随机接受安慰剂、甲泼尼龙或1或2 mg/kg的Hu 23 F2 G治疗3天。 受试者在治疗后随访1年。 这项试验的结果正在分析中。
英文摘要
The study was designed to evaluate the efficacy & safety of Hu23F2G administered intravenously to patients with acute exacerbations of multiple sclerosis (MS) as compared to placebo and corticosteroid treatment. Hu23F2G is a humanized anti-CD18 monoclonal antibody which has been effective in a non-human primate experimental model of MS. This was a Phase 2 study in which patients will be randomized to treatment for 3 days with placebo, methylprednisoline, or Hu23F2G at 1 or 2 mg/kg. Subjects were be followed for 1 year after treatment. The results of this trial are under analysis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AVONEX IN TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
AVONEX IN TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
COPAXONE IN PATIENTS WITH MULTIPLE SCLEROSIS--OPEN LABEL STUDY
SAFETY OF TIZANIDINE IN PATIENTS WITH MS--OPEN LABEL EVALUATION